POLG抗体;POLG Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-5: 231, Jurkat, Hela, 293T cell and Mouse heart tissue lysates, Primary antibody: P09941(CALCOCO1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09941(CALCOCO1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09941(CALCOCO1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The POLG antibody targets DNA polymerase gamma (POLG), the enzyme responsible for mitochondrial DNA (mtDNA) replication and repair. Encoded by the nuclear POLG gene, this 140 kDa protein consists of an N-terminal domain, exonuclease domain, and polymerase domain. As the sole DNA polymerase in mitochondria, POLG's functional integrity is critical for maintaining mtDNA copy number and fidelity. Mutations in POLG are linked to mitochondrial disorders like progressive external ophthalmoplegia (PEO), ataxia-neuropathy syndromes, and Alpers-Huttenlocher syndrome, often manifesting as mtDNA depletion or deletion.

POLG antibodies are essential tools in researching mitochondrial dysfunction. They enable detection of POLG expression levels via Western blot, immunohistochemistry, or immunofluorescence, helping correlate protein abnormalities with disease phenotypes. Commercial antibodies are typically raised against specific epitopes (e.g., C-terminal regions) and validated for specificity across human and model organisms. In diagnostics, POLG antibodies assist in confirming pathogenic variants identified through genetic testing. Recent studies also explore POLG's role in aging, neurodegeneration, and chemotherapy-induced toxicity, emphasizing its broader biomedical relevance. However, antibody validation remains crucial due to potential cross-reactivity with other polymerases or truncated variants in disease states.